作者投稿
专家审稿
编辑办公
邮件订阅
RSS
The Application of Magnetic Resonance Functional Imaging in Efficacy Assessment of Neoadjuvant Chemotherapy for Breast Cancer
-
摘要:
乳腺癌是女性常见疾病之一, 其死亡率已跃居我国女性恶性肿瘤的第一位。因此, 乳腺癌早期发现、早期诊断和早期治疗已经成为乳腺疾病的工作重点。新辅助化疗是局部进展期乳腺癌的标准治疗方案, 磁共振成像在乳腺癌新辅助化疗疗效评估方面优于超声、X线和临床检查。磁共振不仅能进行结构成像, 也可进行功能成像。磁共振动态增强成像、扩散加权成像、灌注成像及磁共振波谱等功能技术在乳腺癌疗效评估中的应用受到广泛关注。
Abstract:Breast cancer is one of the common diseases in women, and its mortality now ranks first among the female malignancies in China. Therefore, early detection, early diagnosis and early treatment have become the focus of the treatment for breast diseases. Neoadjuvant chemotherapy is a standard treatment for locally progressive breast cancer, and magnetic resonance imaging (MRI) is superior to ultrasonography, X-ray and clinical examination in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer. MRI can provide not only structural imaging, but also functional imaging. MRI dynamic contrast enhanced imaging, diffusion weighted imaging, perfusion weighted imaging and magnetic resonance spectroscopy have received extensive attention in the evaluation of therapeutic efficacy for breast cancer.
-
[1] Chen W. Cancer statistics:updated cancer burden in China[J]. Chin J Cancer Res, 2015, 27:1. http://d.wanfangdata.com.cn/Periodical/zgazyj201501001 [2] Youlden DR, Cramb SM, Dunn NA, et al. The descriptive epidemiology of female breast cancer:an international comparison of screening, incidence, survival and mortality[J]. Cancer Epidemiol, 2012, 36:237-248. doi: 10.1016/j.canep.2012.02.007 [3] Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer[J]. Ann Surg Oncol, 2012, 19:1508-1516. doi: 10.1245/s10434-011-2108-2 [4] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis[J]. Lancet, 2014, 384:164-172. doi: 10.1016/S0140-6736(13)62422-8 [5] Pennisi A, Kieber-Emmons T, Makhoul I, et al. Relevance of pathological complete response after neoadjuvant therapy for breast cancer[J]. Breast Cancer (Auckl), 2016, 10:103-106. http://europepmc.org/articles/PMC4961053/ [6] Schaefgen B, Mati M, Sinn HP, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response?[J]. Ann Surg Oncol, 2016, 23:789-795. doi: 10.1245/s10434-015-4918-0 [7] Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer:MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL[J]. Radiology, 2012, 263:663-672. doi: 10.1148/radiol.12110748 [8] Bollet MA, Thibault F, Bouillon K, et al. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers:a prospective phase Ⅱ study[J]. Int J Radiat Oncol Biol Phys, 2007, 69:13-18. doi: 10.1016/j.ijrobp.2007.02.020 [9] Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis[J]. Curr Top Microbiol Immunol, 1999, 237:97-132. [10] Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer[J]. Clin Cancer Res, 2008, 14:6580-6589. doi: 10.1158/1078-0432.CCR-07-4310 [11] Tudorica A, Oh KY, Chui SY, et al. Early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy using quantitative DCE-MRI[J]. Transl Oncol, 2016, 9:8-17. doi: 10.1016/j.tranon.2015.11.016 [12] Wang GS, Zhu H, Bi SJ. Pathological features and prognosis of different molecular subtypes of breast cancer[J]. Mol Med Rep, 2012, 6:779-782. doi: 10.3892/mmr.2012.981 [13] Yoo C, Ahn JH, Jung KH, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy[J]. J Breast Cancer, 2012, 15:203-210. doi: 10.4048/jbc.2012.15.2.203 [14] Drisis S, Metens T, Ignatiadis M, et al. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer:the impact of breast cancer subtypes on the diagnostic accuracy[J]. Eur Radiol, 2016, 26:1474-1484. doi: 10.1007/s00330-015-3948-0 [15] Li SP, Padhani AR, Taylor NJ, et al. Vascular characterisation of triple negative breast carcinomas using dynamic MRI[J]. Eur Radiol, 2011, 21:1364-1373. doi: 10.1007/s00330-011-2061-2 [16] Koo HR, Cho N, Song IC, et al. Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers[J]. J Magn Reson Imaging, 2012, 36:145-151. doi: 10.1002/jmri.23635 [17] Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer[J]. Cancer Imaging, 2006, 6:135-143. doi: 10.1102/1470-7330.2006.0021 [18] Sharma U, Danishad KK, Seenu V, et al. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy[J]. NMR Biomed, 2009, 22:104-113. doi: 10.1002/nbm.1245 [19] Liu S, Ren R, Chen Z, et al. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy[J]. J Magn Reson Imaging, 2015, 42:779-787. doi: 10.1002/jmri.24843 [20] Che S, Zhao X, Ou Y, et al. Role of the intravoxel incoherent motion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer[J]. Medicine (Baltimore), 2016, 95:e2420. doi: 10.1097/md.0000000000002420 [21] Lee Y, Lee SS, Kim N, et al. Intravoxel incoherent motion diffusion-weighted MR imaging of the liver:effect of triggering methods on regional variability and measurement repeatability of quantitative parameters[J]. Radiology, 2015, 274:405-415. doi: 10.1148/radiol.14140759 [22] Andreou A, Koh DM, Collins DJ, et al. Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases[J]. Eur Radiol, 2013, 23:428-434. doi: 10.1007/s00330-012-2604-1 [23] Park HJ, Sung YS, Lee SS, et al. Intravoxel incoherent motion diffusion-weighted MRI of the abdomen:The effect of fitting algorithms on the accuracy and reliability of the parameters[J]. J Magn Reson Imaging, 2017, 45:1637-1647. doi: 10.1002/jmri.25535 [24] 张绪良, 周俊伟, 毛哲玉, 等.磁共振灌注成像对局部进展期乳腺癌新辅助化疗疗效的评估价值[J].中国CT和MRI杂志, 2016, 14:75-77, 88. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgcthmrizz201605024 [25] Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions[J]. J Natl Cancer Inst, 2002, 94:1197-1203. doi: 10.1093/jnci/94.16.1197 [26] Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer:predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4 T[J]. Radiology, 2004, 233:424-431. doi: 10.1148/radiol.2332031285 [27] Tozaki M, Sakamoto M, Oyama Y, et al. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method[J]. J Magn Reson Imaging, 2010, 31:895-902. doi: 10.1002/jmri.22118 [28] Baek HM, Chen JH, Nalcioglu O, et al. Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy[J]. Ann Oncol, 2008, 19:1022-1024. doi: 10.1093/annonc/mdn121 -
点击查看大图
计量
- 文章访问数: 234
- HTML全文浏览量: 49
- PDF下载量: 3
- 被引次数: 0
下载:
